TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

11A.44 Centers for Disease Control and Prevention (CDC). Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection. Morb Mortal Wkly Rep 2003;52:735-9. 11A.45 Sneag DB et al. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases. Pediatr Infect Dis J 2007;26:1142-6. 11A.46 Schaaf HS. Evaluation of young children with adult multidrug resistant tuberculosis: a 30 months follow-up. Pediatrics 2002;109:765-71. 11A.47 Ena J et al. Short course therapy with rifampin plus isoniazid compared with standard therapy with isoniazid for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6. 11A.48 Cook PP et al. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection. Clin Infect Dis 2006;43:271-5. 11A.49 Spyridis NP et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-months regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22. 11A.50 Vlaamse Vereniging voor Respiratoire gezondheidszorg en Tuberculosebestrijding (VRGT). Behandeling van multiresistente tuberculose. Available at: http://www.vrgt.be/uploads/documentenbank/c0f5 6dd01ebc223b0cefa5fc1babd862.pdf. Accessed on August 9th 2010. 11A.51 Fonds des affections Respiratoires et pour l‘Education à la Santé (FARES). La tuberculose à germes multirésistants. Available at: http://www.fares.be/documents/Faresfr.pdf. Accessed on August 9th 2010. 11A.52 Chaulk CP et al. Directly observed therapy for treatment completion of pulmonary tuberculosis. J Am Med Assoc 1998;279:943-8. 11A.53 Bofinger JJ et al. Fever of unknown origin caused by tuberculosis. Infect Dis Clin North Am 2007; 21:947-62. 11A.54 Maartens G et al. Tuberculosis. Lancet 2007;370:2030-43. 11A.55 Connelly Smith K et al. A review of tuberculosis: reflections on the past, present and future of a global epidemic disease. Expert Rev Anti Infect Ther 2003;1:483-91. 11A.56 Centers for Disease Control and Prevention (CDC). Treatment of tuberculosis. Morb Mortal Wkly Rep 2003;52(RR-11):1-77. 11A.57 Myers JP. New recommendations for the treatment of tuberculosis. Curr Opin Infect Dis 2005;18: 133-40. 11A.58 Daley CL. Update in tuberculosis 2009. Am J Respir Crit Care Med 2010;181:550-5. 11A.59 Ralph AP et al. Tuberculosis into the 2010s: is the glass half full? Clin Infect Dis 2009;49:574-83. 11A.60 Campbell IA et al. Pulmonary tuberculosis: diagnosis and treatment. Br Med J 2006;332:1194-7. 11A.61 Rikimaru T. Endobronchial tuberculosis. Expert Rev Anti Infect Ther 2004;2:245-51. 11A.62 Golden MP et al. Extrapulmonary tuberculosis: an overview. Am Fam Physician 2005;72:1761-8. 11A.63 Jacob JT et al. Acute forms of tuberculosis in adults. Am J Med 2009;122:12-7. 11A.64 Sharma SK et al. Miliary tuberculosis: new insights into an old disease. Lancet Infect Dis 2005;5: 415-30. 11A.65 Gardam M et al. Mycobacterial osteomyelitis and arthritis. Infect Dis Clin North Am 2005;19:819-30. 11A.66 Thwaites GE et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005;192:79-88. 11A.67 Donald PR bet al. Tuberculous meningitis. N Engl J Med 2004;351:1719-20. 11A.68 Patel VB et al. Multidrug resistant tuberculous meningitis in KwaZulu – Natal, South Africa. Clin Infect Dis 2004;38:851-6. 11A.69 Rock RB et al. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 2008;21:243-61. 11A.70 Donoghue SD et al. Intestinal tuberculosis. Curr Opin Infect Dis 2009;22:490-6. 11A.71 Jacob JT et al. Male genital tuberculosis. Lancet Infect Dis 2008;8:335-42. 11A.72 Deiss RG et al. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009;48:72-82. 11A.73 Thwaites GE et al. Dexamethasone for treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351:1741-51. 11A.74 Schoeman JF et al. Effect of corticosteroids on intracranial pressure, computed tomographic findings and clinical outcome in young children with tuberculous meningitis. Pediatrics 1997;99:226-31. 11A.75 Cruz AT et al. Treatment of tuberculosis in children. Expert Rev Anti Infect Ther 2008;6:939-57. 11A.76 Newton SM et al. Paediatric tuberculosis. Lancet Infect Dis 2008;8:498-510. 11A.77 Marais BJ et al. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Respir Crit Care Med 2006;173:1078-90. 11A.78 Bergeron KG et al. Tuberculosis in pregnancy: current recommendations for screening and treatment in the USA. Expert Rev Anti Infect Ther 2004;2:589-98. 11A.79 Swaminathan S et al. HIV-associated tuberculosis: clinical update. Clin Infect Dis 2010;50:1377-86. 11A.80 Sterling TR et al. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 2010;50(suppl. 3):S223-30. 11A.81 Khan FA et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010;50:1288-99. 11A.82 Burman WJ et al. Treatment of HIV related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001;164:7-12. 11A.83 Chukwuka Onyebunoh P et al. Treatment options for HIV-associated tuberculosis. J Infect Dis 2007; 196(suppl. 1):S35-45. 11A.84 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1- 207. 11A.85 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009; 58(RR-11):1-167. 11A.86 Nahid P et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007;175:1199-1206. 11A.87 Abdool Karim SS et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697-706. 11A.88 DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov/content files/ AdultandAdolescentGL.pdf. Accessed on August 9th 2010. 11A.89 Drobniewski F et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST do-
cument E.DEF 8.1). Report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect 2007;13:1144-56. 11A.90 Holtz TH et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006;144:650-9. 11A.91 Cattamanchi A et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009;48:179-85. 11A.92 Mak A et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008;178:306-12. 11A.93 Kwon YS et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502. 11A.94 Chan ED et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008;21:587-95. 11A.95 Eker B et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008;14:1700-6. 11A.96 Orenstein EW et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-61. 11A.97 Di Perri G et al. Which agents should we use for the treatment of multidrug resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004;54:593-602. 11A.98 Chan ED et al. Treatment and outcome analysis of 205 patients with multidrug resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-9. 11A.99 Zignol M et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006;194:479-85. 11A.100 Matteelli A et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 2007;5:857-71. 11A.101 van Helden PD et al. Antimicrobial resistance in tuberculosis: an international perspective. Expert Rev Anti Infect Ther 2006;4:759-66. 11A.102 Abdel Aziz M er al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-Tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54. 11A.103 Drobniewski F et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1). Report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect 2007;13:1144-56. 11A.104 Burman WJ et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-8. 11A.105 Conde MB et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, randomised, controlled phase II trial. Lancet 2009;373:1183-9. 11A.106 Dietze R et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178:1180-5. 11A.107 Schecter GF et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50:49-55. 11A.108 von der Lippe B et al. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB). A report of ten cases. J Infect 2006;52:92-6. 11A.109 LoBue P. Extensively drug-resistant tuberculosis. Curr Opin Infect Dis 2009;22:167-73. 11A.110 Madariaga MG et al. Extensively drug-resistant tuberculosis. Am J Med 2008;121:835-44. 11A.111 Kim DH et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-82. 11A.112 Jeon CY et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis 2008;46:42-9. 11A113 Kwon YS et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008;47:496-502. 11A.114 Chan ED et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008;21:587-95. 11A.115 Eker B et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008;14:1700-6. 11A.116 Banerjee R et al. Extensively drug-resistant tuberculosis: new strains, new challenges. Expert Rev Anti Infect Ther 2008;6:713-24. 11A.117 Jassal M et al. Extensively drug-resistant tuberculosis. Lancet Infect Dis 2009;9:19-30. 11A.118 Cegielski JP. Extensively drug-resistant tuberculosis: ―There must be some kind of way out of here‖. Clin Infect Dis 2010;50(suppl. 3):S195-200. 11A.119 Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs. Worldwide, 2002-2004. Morb Mortal Wkly Rep 2006;55: 301-5. 11A.120 Centers for Disease Control and Prevention (CDC). Extensively drug-resistant tuberculosis. United States,1993-2006. Morb Mortal Wkly Rep 2007;56:250-3. 11A.121 Dukes Hamilton C et al. Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin Infect Dis 2007;45:338-42. 11A.122 Ginsburg AS et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003;37:1448-52. 11A.123 Shah NS et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007;13:380-7. 11A.124 Matteelli A et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 2007;5:857-71. 11A.125 van Helden PD et al. Antimicrobial resistance in tuberculosis: an international perspective. Expert Rev Anti Infect Ther 2006;4:759-66. 11A.126 Abdel Aziz M er al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-Tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54. 11A.127 Mitnick CD et al Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2009;359:563-74. 11B.1 Griffith DE et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175;367-416.
Page 1 and 2:
TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4:
1.89 Laupland KB. Vascular and para
Page 5 and 6:
of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57: factor and other newly approved bio
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100: mortality after kidney transplantat
Page 101 and 102: 33A.1 Kearney BP et al. The penetra
Page 103 and 104: Clin Plast Surg Clinics in Plastic
Page 105 and 106: Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?